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Abstract
Background: Global dissemination of Escherichia coli producing CTX-M extended-spectrum b-lactamases (ESBL) is a public
health concern. The aim of the study was to determine factors associated with CTX-M- producing E. coli infections among
patients hospitalised in the Assistance Publique-Ho ˆpitaux de Paris, the largest hospital system in France (23 000 beds),
through a prospective case-control-control study.
Methods/Principal Findings: From November 2008 to June 2009, 152 inpatients with a clinical sample positive for CTX-M-
producing E. coli (cases), 152 inpatients with a clinical sample positive for non ESBL-producing E. coli on the day or within
the three days following case detection (controls C1), and 152 inpatients with culture-negative clinical samples since the
beginning of hospitalisation and until three days after case detection (controls C2) were included in ten hospitals of the
Paris area. Factors studied were related to patient’s origin, lifestyle and medical history as well as care during hospitalisation.
Those independently associated with CTX-M-producing E. coli were determined. Three independent factors were common
to the two case-control comparisons: birth outside of Europe (cases vs C1: OR1=2.4; 95%CI=[1.3–4.5] and cases vs C2:
OR2=3.1; 95%CI=[1.4–7.0]), chronic infections (OR1=2.9; 95%CI=[1.3–6.9] and OR2=8.7; 95%CI=[2.0–39.7]), and antibiotic
treatment between hospital admission and inclusion (OR1=2.0; 95%CI=[1.0–3.8] and OR2=3.3; 95%CI=[1.5–7.2]). Cases
were also more likely to be (i) functionally dependent before hospitalisation than C2 (OR2=7.0; 95%CI=[2.1–23.5]) and (ii)
living in collective housing before hospitalisation than C2 (OR2=15.2; 95%CI=[1.8–130.7]) when CTX-M-producing E. coli
was present at admission.
Conclusion: For the first time, patient’s origin and lifestyle were demonstrated to be independently associated with
isolation of CTX-M-producing E. coli, in addition to health care-related factors.
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Introduction
Escherichia coli is a universal commensal of humans and several
animal species. It is also one of the most common Enterobacteriaceae
causing extra-intestinal infections [1]. Because of these ecological
features, E. coli is constantly exposed to antibiotics and developing
mechanisms of resistance to antibiotics. Since 2000, E. coli isolates
resistant to extended-spectrum cephalosporins by production of
extended-spectrum b-lactamases (ESBL) have emerged worldwide
in both community and hospital settings [2]. Unfortunately,
ESBL-positive isolates are also commonly resistant to fluoroquin-
olones and cotrimoxazole, two antibiotics widely used to treat
community-onset urinary tract infections (UTI) [2]. The dissem-
ination of these multidrug resistant (MDR) E. coli isolates occurred
concomitantly with the emergence of a new ESBL family called
CTX-M and derived from the chromosomal b-lactamases of
Kluyvera spp., an environmental Enterobacteriaceae [3]. Among the
numerous plasmid-mediated CTX-M enzymes described to date,
CTX-M-1, CTX-M-14 and CTX-M-15 currently predominate
[2,3]. Moreover, a widely disseminated lineage of virulent E. coli,
designated sequence type ST131 according to multilocus sequence
typing and producing CTX-M-15 has been identified [4,5]. The
epidemiology of CTX-M-producing E. coli is complex because
these isolates have become ubiquitous: in the community and in
the hospital in many countries [5], in animals [6,7], and also in the
environment [8]. Therefore, identifying patients at risk for
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30498harbouring ESBL-producing E. coli among all infected patients,
especially those with community-onset infections, is of paramount
importance for both choice of treatment and limitation of the
diffusion of these resistant strains.
The aim of the study was to determine factors associated with
CTX-M- producing E. coli infections among patients hospitalised
in the Assistance Publique-Ho ˆpitaux de Paris (AP-HP), the largest
hospital system in France (23 000 beds) located in Paris area,
through a prospective case-control-control study.
Results
Participants
Among the 264 eligible patients (patients with a clinical isolate
of E. coli producing an ESBL), 174 were pre-included and 90
excluded as indicated in Figure 1. Among the 174 pre-cases, 20
(11.5%) with E. coli producing an ESBL other than CTX-M were
excluded. Therefore, 154 cases had to be included in the study.
However, two cases were secondly removed because one had a
corresponding control C2 with specimen sampled outside the
required time frame, and for the other one, the isolate producing
CTX-M was Klebsiella pneumoniae. Finally, 152 cases with two
controls for each case (304) were included in the study.
A majority of cases and controls were hospitalised in short-term
facilities (cases: n=136, C1: n=139, C2: n=139) and essentially
in adult medical wards (cases: n=96, C1: n=99, C2: n=108).
Hospital death occurred in 12% of cases, 7% of C1, and 5% of C2
patients. The difference was statistically significant between cases
and C2 (p=0.02). Overall, 62% of the samples were from the
urinary tract, 26% from various deep sites (blood, surgically-
sampled specimens, respiratory and ascetic fluid) and 12% from
other sites. There was no statistical difference among the type of
clinical sample according to cases and controls.
CTX-M enzymes
CTX-M-15 accounted for 51% of the CTX-M enzymes
followed by CTX-M-1 (24%), CTX-M-14 (12%), and CTX-M-
27 (4%). The remaining CTX-M consisted of six other CTX-M
enzymes.
First case-control study
Whencases werecomparedtoC1, cases were morelikelythan C1
to be born in a country outside of Europe (odds ratio [OR]=2.3;
95% confidence interval [CI]=1.3–4.0) (Table 1). Among the 52
cases born in a country outside of Europe, 34.5% were born in Asia,
34.5% inNorth Africa,27% insub-Saharan Africaand 4%inSouth
America. In addition, cases were more likely than C1 to live outside
of Europe (OR=5.0; 95%CI=1.1–22.8) (Table 1); to have been
hospitalised $10 days (OR=3.0; 95%CI=1.6–5.6) within the last
six months; to have recurrent UTI or chronic skin infections
(OR=3.4; 95%CI=1.6–7.2),and invasivedevices withinthe lastsix
months (OR=1.9; 95%CI=1.1–3.1); to have received an antibiotic
treatment within the last month (OR=2.6; 95%CI=1.5–4.6),
especially $5 days (OR=2.2; 95%CI=1.1–4.4), cotrimoxazole
(OR=10.0; 95%CI=1.3–78.8) or extended-spectrum cephalospo-
rins (OR=5.5; 95%CI=1.2–24.8) (Table 2). Regarding the current
hospitalisation (Table 3), cases were more likely than C1 to have had
intravascular devices (OR=2.0; 95%CI=1.1–3.6) and received
antibiotics between admission and inclusion (OR=2.6;
95%CI=1.4–4.6), especially for a duration $5 days (OR=3.3;
95%CI=1.6–6.7). On the opposite, cases were less likely than C1 to
eatrawmeat(OR=0.5;95%CI=0.3–0.9),and to havecontactwith
pets or livestock (OR=0.5; 95%CI=0.3–0.9) (Table 2). Of note,
there was no statistical difference between cases and C1 regarding
the characteristics of household members, i.e. number, age,
occupation in healthcare facilities, and medical history.
Figure 1. Flow chart for inclusion.
doi:10.1371/journal.pone.0030498.g001
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associated with a CTX-M-producing E. coli isolate were country
of birth outside of Europe (OR=2.4; 95%=1.3–4.5), recurrent
UTI or chronic skin infections (OR=2.9; 95%CI=1.3–6.9),
previous hospitalisation (OR=2.0; 95%CI=1.1–3.6), antibiotic
treatment and ICU hospitalisation between admission and
inclusion (OR=2.0; 95%CI=1.0–3.8, and OR=2.3;
95%CI=1.1–5.0, respectively).
Second case-control study
When cases were compared to C2, univariate analysis showed
that living in a country outside of Europe, contact with pets or
livestock, cotrimoxazole or extended-spectrum cephalosporin
treatments, and an antibiotic treatment $5 days were no longer
associated with isolation of CTX-M-producing E. coli (Tables 1 and
2). However, 16 additional factors were identified (Tables 1 and 2):
age $80 years (OR=2.1; 95%CI=1.1–4.0), female gender
(OR=1.7; 95%CI=1.1–2.8), collective housing (OR=10.4;
95%CI=2.4–44.8), functional dependence before hospitalisation
(OR=5.1; 95%CI=2.3–11.6), previous hospitalisation in another
country than France (OR=8.0; 95%CI=1.0–64.0), previous
fluoroquinolone treatment (OR=3.7; 95%CI=1.0–13.1), and at
least one comorbidity (OR=2.1; 95%CI=1.4–3.4). The nine
remaining factors were linked to the current hospitalisation
(Table 3). Of interest, living alone (Table 1) was inversely associ-
ated with isolation of CTX-M-producing E. coli (OR=0.4;
95%CI=0.2–0.8)
In the multivariate analysis comparing cases and C2 (Table 4),
four factors not identified in the first multivariate analysis
comparing cases to C1 were found independently associated with
isolation of CTX-M-producing E. coli: female gender (OR=2.5;
95%CI=1.2–5.2), functional dependence before hospitalisation
(OR=7.0; 95%CI=2.1–23.5), previous urinary drainage
(OR=4.4; 95%CI=1.6–11.5), and at least one invasive device
between admission and inclusion (OR=4.2; 95%CI=1.6–10.8).
Subpopulation analysis of cases with an imported CTX-
M-producing E. coli isolate
Among the 66 cases with a CTX-M-producing E. coli clinical
sample detected within the first 48 h of hospitalisation (i.e.
imported), only 33 had a C1 for whom the non-ESBL-producing
E. coli isolate was detected within the same time frame, whereas all
had a C2. In univariate analysis, the 33 cases were more likely
than C1 (Table 5) to live in collective housing (OR=5.0;
95%CI=1.1–22.8); to have a previous hospitalisation (OR=4.9;
95%CI=1.4–17.3), and at least one invasive device in the last six
months (OR=7.0; 95%CI=1.6–30.8). All these variables, except
for previous hospitalisation, were also significantly associated with
an imported CTX-M-producing E. coli isolate when the 66 cases
were compared to C2 (Table 6). Moreover, the cases-C2
comparison showed that functional dependence before hospital-
isation (OR=4.0; 95%CI=1.1–14.2), and antibiotic treatment in
the last month (OR+2.5; 95%CI=1.1–5.7) were also associated
factors (Table 6). Finally, consumption of raw meat was inversely
Table 1. Univariate analysis of demographic and lifestyle factors associated with a CTX-M-producing E. coli clinical isolate through
a case (patient with a CTX-M producing E. coli isolate) - control (C1: patient with a non-ESBL-producing E. coli isolate) - control (C2:
patient with negative clinical samples) study.
Factor Case No. (%) C1 No. (%) Odds ratio (95% CI) P value C2 No. (%) Odds ratio (95% CI) P value
Demographic data
Age (mean 6 SD) in years 64625 64622 1.0 (1.0–1.0) 0.7 61622 1.0 (1.0–1.0) 0.1
Age ,15 years 9 (6) 3 (2) 7.0 (0.9–56.9) 0.07 3 (2) 7.0 (0.9–56.9) 0.07
Age $65 years 84 (55) 85 (56) 1.0 (0.6–1.6) 0.9 77 (51) 1.3 (0.8–2.2) 0.3
Age $80 years 49 (32) 45 (30) 1.2 (0.7–2.1) 0.6 35 (23) 2.1 (1.1–4.0) 0.03
Female 99 (65) 93 (61) 1.2 (0.7–1.9) 0.5 79 (52) 1.7 (1.1–2.8) 0.02
Country of birth outside of Europe 51 (34) 27 (18) 2.3 (1.3–4.0) 0.003 29 (19) 2.0 (1.2–3.4) 0.007
Living in a country outside of Europe 11 (7) 3 (2) 5.0 (1.1–22.8) 0.04 6 (4) 2.0 (0.7–5.9) 0.2
Lifestyle
Collective housing 27 (18) 21 (14) 1.8 (0.8–3.8) 0.2 10 (7) 10.4 (2.4–44.8) 0.002
Individual housing (.2 household members) 44 (29) 34 (22) 1.7 (0.9–3.0) 0.09 37 (24) 1.5 (0.9–2.6) 0.2
Live alone 34 (22) 40 (26) 0.8 (0.4–1.4) 0.4 56 (37) 0.4 (0.2–0.8) 0.005
Functionally dependent before hospitalisation. 49 (32) 36 (24) 1.7 (1.0–3.0) 0.07 20 (13) 5.1 (2.3–11.6) ,10
24
Patients not working 107 (84) 116 (92) 0.7 (0.4–1.2) 0.2 98 (91) 1.4 (0.8–2.5) 0.2
Retired patients 88 (69) 93 (74) 0.8 (0.5–1.4) 0.5 75 (69) 1.6 (0.9–2.6) 0.09
Consumption of - $7 raw vegetables/week 85 (69) 86 (68) 0.9 (0.4–1.6) 0.6 100 (77) 0.5 (0.3–1.0) 0.07
- poultry$twice a week 71 (58) 71 (56) 1.1 (0.6–1.9) 0.8 79 (60) 0.9 (0.5–1.6) 0.7
- beef$twice a week 78 (64) 87 (70) 0.8 (0.5–1.4) 0.5 92 (70) 0.7 (0.4–1.3) 0.3
Consumption of raw meat 37 (24) 57 (38) 0.5 (0.3–0.9) 0.02 57 (38) 0.5 (0.3–0.9) 0.01
Community meal 81 (53) 85 (56) 0.9 (0.5–1.5) 0.6 87 (57) 0.8 (0.5–1.4) 0.4
Practice of a sport 11 (7) 11 (7) 1.0 (0.4–2.4) 1.0 21 (14) 0.5 (0.2–1.0) 0.06
Pets or livestock 19 (13) 36 (24) 0.5 (0.3–0.9) 0.02 31 (20) 0.6 (0.3–1.1) 0.08
Travel abroad in the preceding 6 months (.14 days) 17 (11) 14 (9) 1.2 (0.6–2.6) 0.6 17 (11) 1.0 (0.5–2.0) 1.00
doi:10.1371/journal.pone.0030498.t001
Factors Associated with CTX-M-Producing E. coli
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30498associated (OR=0.4; 95%CI=0.2–0.9) with an imported CTX-
M-producing E. coli isolate (Table 6).
In multivariate analysis, factors independently associated with
an imported CTX-M-producing E. coli isolate were to have at least
one invasive device in the last six months (OR=7.0;
95%CI=1.6–30.8), when comparing cases to C1, and collective
housing (OR=15.2; 95%CI=1.8–130.7) and intravascular devic-
es in the last six months (OR=2.9; 95%CI=1.2–6.9), when
comparing cases to C2.
Discussion
CTX-M-producing E. coli are spreading worldwide, and it is
suggested that transmission occurs mainly in the community [2].
Therefore, besides classical factors linked to MDR bacteria
carriage, the present study focused on variables reflecting patient’s
lifestyle and history before hospitalisation that may expose to
CTX-M-producing E. coli in the community. Thus, we showed
that country of birth was significantly associated with isolation of
E. coli producing CTX-M. Moreover, being born outside of
Europe was identified in the two case-control studies. Ninety six
percent of foreign-born cases originated from Africa and Asia, two
regions well known for immigration to France. The rather elevated
median age of foreign-born cases (64 years) suggests that these
immigrants have been living in France for several years. In
addition, the proportion of recent travel among cases was quite
low (11%) and travel abroad was not significantly associated with
isolation of CTX-M-producing E. coli [9]. Therefore, the
hypothesis that recent travels of foreign-born cases to their
country of birth with a high prevalence of ESBL-producing
Enterobacteriaceae does not seem to hold [10–13]. However, foreign-
born cases are more likely than French-born cases to be in contact
with recent immigrants or relatives living in countries with high
prevalence of ESBL, this may increase the exposition of the former
to MDR bacteria cross-transmission [14]. Specific studies should
be conducted to address this hypothesis.
The second case-control study (cases vs C2) demonstrated for
the first time that functional dependence before hospitalisation was
also associated with isolation of CTX-M- producing E. coli. This
suggests that the need for living assistance at home may promote
cross-transmission by close contact between cases and relatives or
professionals and subsequently increases the risk for bacterial
transmission.
Of interest, chronic infections were found as associated with
isolation of CTX-M-producing E. coli. Chronic infections might
lead to repeated use of antibiotics. Such repeated regimens may
enhance the persistence and the predominance of resistant
bacteria such as CTX-M-producing E. coli in the digestive flora
and promote thereafter extra-intestinal infections. This hypothesis
is reinforced by the fact that the two case-control studies linked
Table 2. Univariate analysis of medical history-related factors associated with a CTX-M-producing E. coli clinical isolate through a
case (patient with a CTX-M producing E. coli isolate) - control (C1: patient with a non-ESBL-producing E. coli isolate) - control (C2:
patient with negative clinical samples) study.
Factor Case No. (%) C1 No. (%) Oddsratio (95% CI) P value C2 No. (%) Odds ratio (95% CI) P value
Medical history
In the preceding 6 months
- hospitalised 97 (63) 68 (45) 2.5 (1.5–4.1) 7610
24 79 (52) 1.7 (1.1–2.8) 0.03
- hospitalised $10 days 61 (40) 35 (23) 3.0 (1.6–5.6) 4610
24 43 (28) 1.9 (1.0–3.1) 0.02
- hospitalised ,10 days 36 (24) 33 (22) 1.7 (0.9–3.5) 0.1 36 (24) 1.4 (0.6–2.9) 0.4
- hospitalised outside of France 8 (5) 2 (1) 4.0 (0.8–18.8) 0.08 1 (1) 8.0 (1.0–64.0) 0.05
- at least one invasive device 96 (63) 76 (50) 1.9 (1.1–3.1) 0.02 73 (48) 1.9 (1.2–3.0) 0.009
N urine drainage 47 (31) 28 (19) 2.0 (1.2–3.6) 0.01 14 (9) 4.8 (2.3–10.4) ,10
24
N mechanical ventilation 13 (9) 5 (3) 3.0 (1.0–9.3) 0.06 6 (4) 2.7 (0.9–8.6) 0.08
N intravascular devices 91 (61) 65 (43) 2.0 (1.3–3.3) 0.003 64 (43) 1.9 (1.2–3.1) 0.007
N colonoscopy, endoscopy, 37 (26) 29 (20) 1.5 (0.8–2.9) 0.2 28 (19) 1.5 (0.8–2.6) 0.2
Surgery during the last month 44 (29) 44 (29) 1.0 (0.6–1.7) 0.9 33 (22) 1.6 (0.9–3.0) 0.1
Prothesis within the last year 10 (6) 11 (7) 0.8 (0.3–2.1) 0.6 9 (6) 1.3 (0.5–3.8) 0.6
Antibioticinthemonthprecedinghospitalisation. 53 (35) 25 (16) 2.6 (1.5–4.6) 6610
24 33 (22) 1.9 (1.1–3.1) 0.02
- cotrimoxazole 10 (7) 1 (1) 10.0 (1.3–78.1) 0.03 4 (3) 2.5 (0.8–8.0) 0.1
- fluoroquinolones 11 (7) 7 (5) 1.7 (0.6–4.6) 0.3 3 (2) 3.7 (1.0–13.1) 0.05
- extended spectrum cephalosporins 11 (7) 2 (1) 5.5 (1.2–24.8) 0.03 7 (5) 1.6 (0.6–4.1) 0.4
- penicillins 17 (11) 8 (5) 2.5 (1.0–6.4) 0.06 18 (12) 0.9 (0.5–1.9) 0.9
- $5 days 31 (20) 16 (10) 2.2 (1.1–4.4) 0.02 28 (18) 1.1 (0.6–1.9) 0.7
Nursing or physiotherapy before hospitalisation. 26 (17) 25 (16) 1.1 (0.6–2.0) 0.9 17 (11) 1.7 (0.9–3.4) 0.1
At least one co-morbidity 90 (59) 77 (51) 1.5 (0.9–2.4) 0.1 58 (38) 2.1 (1.4–3.4) 9610
24
- ecurrenturinarytractorchronicskininfections 39 (26) 17 (11) 3.4 (1.6–7.2) 0.001 4 (3) 12.7 (3.9–410) ,610
24
- obstructive bronchial pulmonary disease 7 (5) 4 (3) 1.8 (0.5–6.0) 0.4 4 (3) 1.7 (0.5–5.1) 0.4
- cancer 37 (24) 35 (23) 1.1 (0.3–1.8) 0.8 28 (18) 1.4 (0.8–2.4) 0.2
- diabetes 34 (22) 34 (22) 1.0 (0.6–1.8) 1.0 28 (19) 1.3 (0.7–2.3) 0.4
doi:10.1371/journal.pone.0030498.t002
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coli. However, in multivariate analysis, the link involved antibiotics
received after hospital admission and not those received within the
month preceding admission. This point has never been identified
obviously because differentiating between these two time-periods
of antibiotic exposure was seldom done in previous studies. Of
note, the use of antibiotic during both periods was identified as a
risk factor for CTX-M-producing E. coli detection in univariate
analysis. The lack of relationship between antibiotic use during the
month preceding admission and CTX-M-producing E. coli
through the multivariate analysis suggests that, either, the more
recent the antibiotic use (i.e. administered during hospitalisation),
the stronger the association would be, or other factors indepen-
dently associated with CTX-M-producing E. coli are more
prominent than antibiotic use before hospitalisation.
Most other factors identified in the present study are clearly
related to the healthcare system, suggesting that hospital setting is
a reservoir of E. coli producing CTX-M. On the opposite,
collective housing, which was associated with an imported CTX-
M producing E. coli isolate, suggests that a reservoir of CTX-M-
producing E. coli exists outside of the hospital setting. From this
point of view, a high proportion of residents of Irish nursing homes
has been found to carry ESBL-producing E. coli [15]. Therefore,
collective housing as well as the other risk-factors of isolation of
CTX-M-producing E. coli should be part of the standard medical
interview of patients suspected of infection.
Finally, the present study failed to identify numerous factors
previously associated with a clinical sample positive for ESBL-
producing E. coli such as travel abroad [9], co-morbidities
[9,16,17], transfer from another hospital [18], or previous use of
oxyimino b-lactams [19–21].
In addition, our population-based study did not identify diet or
food habits as a factor associated with CTX-M-producing E. coli.
On the contrary, raw meat consumption was shown to be inversely
associated with CTX-M-producing E. coli in univariate analysis,
which seems to be in contradiction with recent data showing raw
chicken meat to be contaminated by CTX-M-producing E. coli
[22,23]. However, consumption of contaminated raw chicken
meat as a source of CTX-M-producing E. coli in humans has never
been demonstrated. Raw meat consumption in our studied
population is likely to be a surrogate for French-born status
because the populations at risk in our study are foreign-born
persons that are used to eating well-cooked meat.
To our knowledge, this study is the first prospective, multicentre
case-control-control study on factors associated with CTX-M-
producing E. coli in any type of clinical specimens obtained either
within or after the first 48 h of hospitalisation. Indeed, most
previous studies were retrospective or cohort studies [9,16,20,24–
Table 3. Univariate analysis of current hospitalisation-related factors associated with a CTX-M-producing E. coli clinical isolate
through a case (patient with a CTX-M producing E. coli isolate) - control (C1: patient with a non-ESBL-producing E. coli isolate) -
control (C2: patient with negative clinical samples) study.
Factor
Case
No. (%) C1 No. (%)
Odds ratio
(95% CI) P value C2 No. (%)
Odds ratio
(95% CI) P value
Current hospitalisation
Transferred from another hospital 32 (21) 26 (17) 1.5 (0.7–2.9) 0.3 35 (23) 0.8 (0.4–1.7) 0.6
Mc Cabe score 2 34 (25) 20 (15) 1.8 (0.9–3.6) 0.1 22 (16) 1.6 (0.8–2.9) 0.2
Immunocompromised 51 (34) 42 (48) 1.3 (0.8–2.2) 0.3 43 (28) 1.3 (0.8–2.1) 0.3
Between admission and inclusion
- ICU stay 31 (20) 19 (13) 1.8 (1.0–3.2) 0.06 16 (11) 2.9 (1.3–6.4) 0.01
- LTCF stay 35 (23) 38 (25) 0.5 (0.1–2.0) 0.3 29 (19) 3.0 (0.8–11.1) 0.1
- Invasive device during the last week 117 (77) 105 (69) 1.7 (0.9–0.3) 0.07 86 (57) 4.4 (2.2–9.2) ,10
24
N urine drainage 56 (37) 47 (31) 1.3 (0.8–2.1) 0.3 23 (15) 5.1 (2.4–10.9) ,10
24
N mechanical ventilation 24 (17) 17 (12) 1.5 (0.8–3.1) 0.2 7 (5) 9.5 (2.2–40.8) 0.003
N intravascular devices 112 (74) 95 (62) 2.0 (1.1–3.6) 0.02 82 (54) 4.0 (2.0–8.0) ,10
24
- Antibiotic receipt 81 (53) 56 (37) 2.6 (1.4–4.6) 0.001 37 (24) 4.4 (2.4–8.0) ,10
24
N cotrimoxazole 9 (6) 5 (3) 2.0 (0.6–6.6) 0.3 8 (5) 1.1 (0.4–3.1) 0.8
N fluoroquinolones 17 (11) 10 (7) 1.9 (0.8–4.4) 0.2 5 (3) 3.4 (1.2–9.2) 0.02
N penicillins 36 (24) 24 (16) 1.6 (0.9–2.8) 0.1 19 (13) 2.1 (1.1–3.8) 0.02
N extended spectrum cephalosporins 18 (12) 17 (11) 1.1 (0.5–2.1) 0.9 11 (7) 1.9 (0.8–4.4) 0.2
N aminoglycosides 13 (9) 12 (8) 1.1 (0.5–2.6) 0.8 2 (1) 6.5 (1.5–28.8) 0.01
N carbapenems 9 (6) 3 (2) 3.0 (0.8–11.9) 0.1 0 - -
N $5 days 48 (32) 25 (16) 3.3 (1.6–6.7) 9610
24 29 (13) 3.6 (1.9–7.1) 1610
24
Specimen and infection data
- specimen sampled after 48 h of hospitalisation. 86 (57) 92 (61) 0.8 (0.5–1.4) 0.4 63 (41) 1.9 (1.2–3.1) 0.008
- specimen sampled after .10 days of hospitalisation. 56 (37) 51 (33) 1.2 (0.7–1.9) 0.5 31 (20) 2.8 (1.5–5.1) 0.001
- urine sample 97 (64) 104 (68) 0.8 (0.5–1.3) 0.4 81 (53) 1.6 (1.0–2.6) 0.07
- urinary tract infection 100 (66) 104 (68) 0.9 (0.5–1.4) 0.6 - - -
ICU: intensive care unit, LTCF: long-term care facility.
doi:10.1371/journal.pone.0030498.t003
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cases to a single control group comprising patients with a clinical
sample positive for a non-ESBL-producing micro-organism
[17,21,28]. The use of two control-groups, which is a strength of
our study, has two main advantages [29]. First, identifying the
same risk-factors in two case-control studies reinforces the strength
of the association. Second, the ability to identify various risk-
factors is increased by the use of different control populations.
Following this principle, Rodriguez-Bano et al. performed two
case-control studies on the same topic, and used two comparison
groups [19,30]. However, they focused, as many other studies, on
only one type of infection, especially bacteraemia [16,19,20,
28,30], or UTI [21,26], while we did not select for the type of
infection, which is a second strength of our study. Finally, we
investigated both community- and hospital-onset infections on the
contrary to previous studies, which is the third strength of our
study. All these differences may explain the differences observed
between our study and the others regarding factors associated with
isolation of CTX-M-producing E. coli.
Our study has some limitations. We did not search for
asymptomatic faecal carriage in all control-patients. Therefore,
some of these patients may have been misclassified preventing
from identifying some risk-factors. Collective housing has been
assessed as a single factor preventing from identifying specific
populations within this group such as nursing homes or
retirement homes. Finally, antibiotic exposure prior to hospital-
isation was assessed for only one month. Antibiotic exposure
could have been assessed for a longer period of time (6 to 12
months). However, the accuracy of information provided on
antibiotic treatment is likely to decrease with the time span and is
subject to memory bias.
In conclusion, this prospective case-control-control study
identified three types of factors associated with CTX-M-producing
E. coli: those related to the patient medical history, those related to
care provided during hospitalisation, and those associated with
patient’s origin and lifestyle. These new non-healthcare-related
factors, together with those previously identified, such as travel
abroad, warrant further studies in order to get more insight into
the epidemiology of CTX-M-producing E coli, notably in the
community, that is a new real public health concern in both
developed and developing countries.
Methods
Ethical approval
The study was approved by the Ethics Committee of the
Groupe Hospitalier Universitaire Nord (Institutional review board
NuIRB00006477).
Study design and participants
The study was carried out from November 2008 to June 2009 in
ten hospitals of AP-HP (7 554 beds), including short- (n=5) and
long- (n=2) term care facilities as well as paediatric hospitals
(n=3). Factors associated with a clinical sample positive for CTX-
M-producing E. coli in patients hospitalised for at least 24 h, was
studied by using a case-control-control design. We followed the
methodological principles recommended for case-control studies
that analyse risk factors for antibiotic resistance, i.e. controls
derived from the same source population as cases and selected
during the same time periods [29]. Moreover, two different control
groups were selected in order to get a better representation of the
total base population.
Table 4. Multivariate analysis of factors associated with a CTX-M-producing E. coli clinical isolate.
Independent variable Odds ratio (95% CI) P value
Comparison with controls C1
Demographic data
Country of birth outside of Europe 2.4 (1.3–4.5) 0.004
Medical history
Recurrent urinary tract or chronic skin infections 2.9 (1.3–6.9) 0.01
Hospitalised in the preceding 6 months 2.0 (1.1–3.6) 0.01
Current hospitalisation
Having been or being in ICU during the current hospitalisation. 2.3 (1.1–5.0) 0.03
Antibiotic receipt between admission and inclusion. 2.0 (1.0–3.8) 0.04
Comparison with controls C2
Demographic data
Country of birth outside of Europe 3.1 (1.4–6.9) 0.005
Female gender 2.5 (1.2–5.2) 0.02
Lifestyle
Functionally dependent before hospitalisation. 7.0 (2.1–23.5) 0.002
Medical history
Recurrent urinary tract or chronic skin infections 8.7 (1.9–39.7) 0.005
Urine drainage in the preceding 6 months 4.4 (1.6–11.5) 0.003
Current hospitalisation
At least one invasive device between admission and inclusion. 4.2 (1.6–10.8) 0.003
Antibiotic receipt between admission and inclusion. 3.3 (1.5–7.2) 0.003
ICU: intensive care unit.
doi:10.1371/journal.pone.0030498.t004
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tory of each participating hospital with a clinical sample yielding
ESBL-producing E. coli were eligible for the study. To be pre-
included (pre-case), eligible patients had to be still hospitalised,
able to answer a standardised questionnaire, and to have control-
patients. For each pre-case, two controls were selected on the
laboratory register of the same hospital. The first control (C1) was
the first inpatient with a clinical sample positive for a non-ESBL-
producing E. coli the same day or within the three days following
the pre-case detection. The second control (C2) was the first
inpatient with specimen(s) negative for bacterial growth since
admission until three days after the pre-case detection. Pre-cases
were included (cases), as well as their controls, when the ESBL
enzyme was characterised as CTX-M. An isolate was deemed
imported in the hospital when it was detected within the first 48 h
of hospitalisation. Otherwise, it was considered as hospital-
acquired. Written informed consent was obtained from all adult
cases and controls and from parents for child cases and controls.
Variables
One hundred and fourteen variables were prospectively
collected by two investigators in the ten hospitals from inpatients,
their family, medical team, and the bacteriological and medical
files for all cases and controls.
Demographic data. Standard demographic data, including
country of birth and place of residence were collected.
Patient’s lifestyle. Living arrangement was divided into
three categories: individual housing with one or two household
members, individual housing with more than two, and collective
housing (college dormitories, homeless schelters, shelters for
immigrants, homes for young workers, retirement homes and
nursing homes). Patients receiving assistance for daily living before
the current hospitalisation were considered functionally dependent.
Occupation, unemployment, or retirement was clarified. Data on
diet were grouped into four categories according to the type of food.
Meal outside home was recorded. Sport practice, spa use during the
last six months, contact with animals, travel abroad during the last
six months were recorded. If appropriate, chronic infections and
potentialexposuretoMDRE.coli(occupationrelated tohealthorin
a healthcare setting and hospitalisation in the last six months) of
household members were collected.
Medical history. The following variables were collected:
hospitalisation, length of hospital stay, and invasive devices during
the preceding six months; prosthesis during the last year; surgery,
home care, and antimicrobial treatment during the last month. In
addition, co-morbidities (recurrent UTI, chronic skin infections,
obstructive bronchial pulmonary disease, cancer, diabetes or
dialysis) were assessed.
Current hospitalisation. Dates of admission in the hospital
and in the ward in which cases and controls were included, type of
admission (direct or transfer), date of discharge, and in-hospital
death were recorded. The Mc Cabe score was used as a proxy for
underlying illness [31]. A patient was considered immunocom-
promised if he was under immunosuppressive drugs i.e. chemo-
therapy, radiotherapy, or corticosteroids ($30 days or .5 mg/kg
for 5 days); he had haematological disease, metastatic cancer or
HIV-related CD4,500 mm3. Presence of invasive devices within
the last week, and antibacterial treatment between hospital
Table 5. Univariate analysis of factors associated with a CTX-M producing E. coli clinical isolates within the first 48 h of
hospitalisation in subpopulations of cases (patients with a CTX-M producing E. coli isolate) and controls (C1: patients with a non-
ESBL producing E. coli isolate).
Factor* No.(%) of Cases n=33 No. (%) of C1 n=33 Odds ratio (95% CI) P value
Demographic data
Country of birth outside of Europe 8 (24) 6 (18) 1.5 (0.4–5.3) 0.5
Living in a country outside of Europe 1 (3) 0 - -
Lifestyle
Collective housing 16 (48) 8 (24) 5.0 (1.1–22.8) 0.03
Consumption of raw meat 9 (27) 15 (45) 0.4 (0.1–1.3) 0.1
Pets or livestock 4 (12) 4 (12) 1.0 (0.2–4.0) 1.0
Medical history
In the preceding 6 months
- hospitalised 20 (60) 8 (24) 4.9 (1.4–17.3) 0.01
- hospitalised $10 days 10 (30) 4 (12) 3.0 (0.8–11.1) 0.09
- hospitalised ,10 days 10 (30) 4 (12) 4.0 (0.8–18.8) 0.08
- at least one invasive device 23 (70) 11 (33) 7.0 (1.6–30.8) 0.01
N urine drainage 12 (37) 4 (12) 5.0 (1.1–22.8) 0.04
N intravascular devices 22 (69) 9 (28) 5.0 (1.5–17.3) 0.01
Antibiotic receipt in the month preceding hospitalisation. 11 (33) 4 (12) 2.7 (0.9–8.6) 0.08
- cotrimoxazole 3 (9) 0 - -
- extended spectrum cephalosporins 5 (15) 1 (13) 5.0 (0.6–42.8) 0.2
- $5 days 4 (12) 2 (6) 2.0 (0.4–11) 0.4
Recurrent urinary tract or chronic skin infections 5 (15) 3 (9) 2.0 (0.4–10.9) 0.4
Variables presented here comprised those found with a p value (p,0.1) in the comparison between the 33 cases and their controls C1 and those found significant
(p#0.05) in the univariate analysis performed for all cases in comparison with their controls C1.
doi:10.1371/journal.pone.0030498.t005
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sampling and type of clinical specimens positive for CTX-M-
producing E. coli (case) or non-ESBL-producing E. coli (C1) or
culture-negative samples (C2) were collected.
Microbiological analysis
E. coli isolates were locally identified by using the API 20E
system (bioMe ´rieux, Marcy l’Etoile, France). ESBL production
was detected by the double disk synergy test routinely applied in
each laboratory as recommended by the French Antibiog-
ram Committee (http://www.sfm.asso.fr/nouv/general.php?pa=2).
[32,33]E. coli strains screened as ESBL producers were sent to three
laboratories of the ten participating hospitals and sub-cultured on
chromogenic media (bioMe ´rieux). ESBL-encoding bla genes were
searched for by PCR as previously described [34]. Then, the
amplified fragments were sent to Institut Pasteur in Paris to be
sequenced by using primers specific for blaCTX-M, blaTEM and blaSHV
genes, as previously described [34].
Study size
The study size was derived from the total number of patients
with ESBL-producing E. coli available through an active
surveillance programme implemented in each hospital of AP-HP
since more than 15 years [35]. In addition, characterization of the
type of enzyme produced by ESBL-producing E. coli was
performed in 2005, and thus allowing to evaluate the proportion
of CTX-M-producing E. coli among all ESBL-producing E. coli.
Therefore, approximately 260 patients with an ESBL-producing E
.coli isolate were expected during a 6-month study period,
including 180 with E. coli producing CTX-M. With regard to a
risk factor present in 10% of controls, this number of included
cases and controls will allow to detect an odds ratio of 3 with a
power of 90% and a type 1 error of 5%. For a risk factor present in
20% of controls, an odds ratio of 2.4 is expected.
Statistical analysis
For the main objective, comparisons were analysed between
cases and C1 and then between cases and C2. Variables associated
with cases were analysed using conditional logistic regression on
the pairs of 152 cases and their controls. Odds ratios and 95%
confidence intervals were first estimated in univariate analysis.
Variables with a p-value ,0.1 were introduced into the
multivariate analysis and were selected thereafter by using a
backward selection method. The same method was applied to
cases that had a CTX-M-producing E. coli isolated from a
specimen sampled within the first 48 h after hospitalisation, i. e.
imported cases, and their controls which also had a specimen
sampled during the same period. All statistical analyses were
performed with SAS software, version 9.1 (SAS Institute, Cary,
North Carolina). P-values were assessed at the 0.05 level.
Table 6. Univariate analysis of factors associated with a CTX-M producing E. coli clinical isolate within the first 48 h of
hospitalisation in subpopulations of cases (patients with a CTX-M producing E. coli isolate) and controls (C2 : patients with negative
clinical samples).
Factor* No. (%) of Cases n=66 No. (%) of C2 n=66 Odds ratio (95% CI) P value
Demographic data
Age $80 years 19 (29) 15 (23) 1.6 (0.6–4.0) 0.3
Female 44 (67) 37 (56) 1.6 (0.8–3.2) 0.2
Country of birth outside of Europe 18 (27) 11 (17) 1.7 (0.8–3.7) 0.2
Lifestyle
Collective housing 10 (15) 1 (2) 10.0 (1.3–78.1) 0.03
Functionally dependent before hosp. 14 (21) 5 (8) 4.0 (1.1–14.2) 0.03
Live alone 16 (24) 26 (36) 0.6 (0.2–1.2) 0.1
Patients not working 46 (70) 36 (55) 2.1 (1.0–4.7) 0.06
Retired patients 38 (58) 27 (41) 2.2 (1.0–4.9) 0.05
Consumption of raw meat 17 (26) 31 (47) 0.4 (0.2–0.9) 0.01
Pets or livestock 8 (12) 17 (26) 0.4 (0.2–1.1) 0.07
Medical history
In the preceding 6 months
- hospitalised 42 (64) 33 (50) 1.9 (0.9–4.1) 0.1
- hospitalised $10 days 25 (38) 18 (27) 1.8 (0.8–4.0) 0.2
- hospitalised in another country than France 5 (8) 0 - -
- at least one invasive device 47 (71) 35 (53) 2.3 (1.1–5.1) 0.03
N urine drainage 23 (36) 10 (16) 3.0 (1.2–7.6) 0.02
N intravascular device 45 (69) 31 (48) 2.2 (1.0–4.6) 0.04
Antibiotic receipt in the month preceding hosp. 24 (36) 12 (18) 2.5 (1.1–5.7) 0.03
At least one co-morbidity 33 (50) 23 (35) 1.8 (0.9–3.5) 0.1
- recurrent urinary tract or chronic skin infections 10 (15) 1 (2) - -
Variables presented here comprised those found with a p value (p,0.1) in the comparison between the 66 cases and their controls C2 and those found significant
(p#0.05) in the univariate analysis performed for all cases in comparison with their controls C2.
doi:10.1371/journal.pone.0030498.t006
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